Delving into the Latest Updates on Alclometasone Dipropionate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Alclometasone, Alclometasone dipropionate (JAN/USP)

+ [11]

Target

GR

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCongenital Disorders+ [3]

Active Indication

DermatitisPruritusEczema+ [9]

Inactive Indication

Dermatophilosis

Originator Organization

Fougera Pharmaceuticals, Inc.

Active Organization

Shionogi & Co., Ltd.

Aspire Pharma Ltd.

Inactive Organization

Fougera Pharmaceuticals, Inc.

Chongqing Huapont Pharmaceutical Co. Ltd.

Drug Highest PhaseApproved

First Approval Date

US (14 Dec 1982),

Dermatophilosis

Regulation-

Login to view timeline

Structure

Molecular FormulaC28H37ClO7

InChIKeyDJHCCTTVDRAMEH-DUUJBDRPSA-N

CAS Registry66734-13-2

To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent. To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1 mutation, HER-2 mutation or HER-2 amplification).

Start Date26 Dec 2011

Sponsor / Collaborator

Pfizer Inc.

NCT02075632 / CompletedPhase 2

A Mult-Center, Open-Label Study to Evaluate Product Duration of Use Experience With Aclometasone Diproprionate Cream

This is a multi-center, open-label study to evaluate whether participants follow the duration of use instructions for short-term use of alclometasone dipropionate in a population of participants with itchy skin conditions who would use OTC treatments for relief. The study population will be composed of two different cohorts: chronic condition sufferers (eczema or psoriasis) and participants who suffer from occasional itchy skin experiences (such as poison ivy, oak, sumac, insect bites, or skin irritations due to jewelry, cosmetics, detergents, or soaps) where an anti-itch medication would be used.

Start Date01 Sep 2006

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Alclometasone Dipropionate

Login to view more data

100 Translational Medicine associated with Alclometasone Dipropionate

Login to view more data

100 Patents (Medical) associated with Alclometasone Dipropionate

Login to view more data

35

Literatures (Medical) associated with Alclometasone Dipropionate

01 Jan 2024·Traffic

Glucocorticoids rescue cell surface trafficking of R451C Neuroligin3 and enhance synapse formation

Article

Author: De Jaco, Antonella ; Comoletti, Davide ; Bianchi, Sara ; Miranda, Elena ; Trobiani, Laura ; Di Angelantonio, Silvia ; Sollazzo, Raimondo ; Lauro, Clotilde ; Giorda, Ezio ; Serafini, Federica ; Ragozzino, Davide ; Guglielmo, Stefano ; Perfetto, Camilla ; Ferrucci, Laura ; Diamanti, Tamara ; Gioia, Roberta ; Setini, Andrea ; Mautone, Lorenza ; Cacci, Emanuele

AbstractNeuroligins are synaptic cell adhesion proteins with a role in synaptic function, implicated in neurodevelopmental disorders. The autism spectrum disorder‐associated substitution Arg451Cys (R451C) in NLGN3 promotes a partial misfolding of the extracellular domain of the protein leading to retention in the endoplasmic reticulum (ER) and the induction of the unfolded protein response (UPR). The reduced trafficking of R451C NLGN3 to the cell surface leads to altered synaptic function and social behavior. A screening in HEK‐293 cells overexpressing NLGN3 of 2662 compounds (FDA‐approved small molecule drug library), led to the identification of several glucocorticoids such as alclometasone dipropionate, desonide, prednisolone sodium phosphate, and dexamethasone (DEX), with the ability to favor the exit of full‐length R451C NLGN3 from the ER. DEX improved the stability of R451C NLGN3 and trafficking to the cell surface, reduced the activation of the UPR, and increased the formation of artificial synapses between HEK‐293 and hippocampal primary neurons. The effect of DEX was validated on a novel model system represented by neural stem progenitor cells and differentiated neurons derived from the R451C NLGN3 knock‐in mouse, expressing the endogenous protein. This work shows a potential rescue strategy for an autism‐linked mutation affecting cell surface trafficking of a synaptic protein.

01 Jan 2021·Pediatric DermatologyQ4 · MEDICINE

Comparing prescribing patterns for topical corticosteroids based on their FDA indication by age

Q4 · MEDICINE

Article

Author: Cline, Abigail ; Feldman, Steven R. ; Fleischer, Alan B. ; Balogh, Esther A. ; Freeze, Megan E.

AbstractBackground/ObjectivesAtopic dermatitis (AD) affects up to 20% of the pediatric population, with a growing prevalence over the past 30 years. Topical corticosteroids (TCS) are commonly used as a first‐line topical therapy for AD and are prescribed in 59% of all AD visits. However, some topical corticosteroids are prescribed outside of their age range indications. This paper aims to explore the frequency with which topical corticosteroids are prescribed for AD outside of their FDA‐approved age range.MethodsData on prescribing patterns for AD were obtained from the National Ambulatory Medical Care Survey (NAMCS). We assessed the frequency of off‐label use of topical corticosteroids with respect to age indications in four specific age‐groups, as delineated in the data (0‐1, 2‐7, 8‐18, and 19+ years).ResultsAll prescribed topical corticosteroids found in the NAMCS database have an indication for AD or other inflammatory dermatoses or pruritic dermatoses. However, some medications were prescribed outside of their FDA‐approved age indications. These off‐label prescription rates ranged from 52% for desoximetasone to 0% for halobetasol and alclometasone, or rates lower than could be detected by our study.ConclusionsMuch like other medications for AD treatment, TCS are sometimes used off‐label. The off‐label use of topical corticosteroids to treat pediatric AD highlights a gap between clinical practice and regulating guidelines. Additional pediatric studies would offer a greater body of evidence to maintain or expand label indications for the use of TCS in younger patients.

01 Dec 2016·BMC Pharmacology and Toxicology

Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders

Article

Author: Wittenberg, Gayle M ; Narayan, Vaibhav A ; Sun, Yu

BACKGROUNDSide effects, or the adverse effects of drugs, contain important clinical phenotypic information that may be useful in predicting novel or unknown targets of a drug. It has been suggested that drugs with similar side-effect profiles may share common targets. The diagnostic class, Major Depressive Disorder, is increasingly viewed as being comprised of multiple depression subtypes with different biological root causes. One 'type' of depression generating substantial interest today focuses on patients with high levels of inflammatory burden, indicated by elevated levels of C-reactive proteins (CRP) and pro-inflammatory cytokines such as interleukin 6 (IL-6). It has been suggested that drugs targeting the immune system may have beneficial effect on this subtype of depressed patients, and several studies are underway to test this hypothesis directly. However, patients have been treated with both anti-inflammatory and antidepressant compounds for decades. It may be possible to exploit similarities in clinical readouts to better understand the antidepressant effects of immune-related drugs.METHODSHere we explore the space of approved drugs by comparing the drug side effect profiles of known antidepressants and drugs targeting the immune system, and further examine the findings by comparing the human cell line expression profiles induced by them with those induced by antidepressants.RESULTSWe found 7 immune-modulators and 14 anti-inflammatory drugs sharing significant side effect profile similarities with antidepressants. Five of the 7 immune modulators share most similar side effect profiles with antidepressants that modulate dopamine release and/or uptake. In addition, the immunosuppressant rapamycin and the glucocorticoid alclometasone induces transcriptional changes similar to multiple antidepressants.CONCLUSIONSThese findings suggest that some antidepressants and some immune-related drugs may affect common molecular pathways. Our findings support the idea that certain medications aimed at the immune system may be helpful in relieving depressive symptoms, and suggest that it may be of value to test immune-modulators for antidepressant-like activity in future proof-of-concept studies.

100 Deals associated with Alclometasone Dipropionate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01820	Alclometasone Dipropionate	D07AB10 S01BA10	DB00240

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dermatitis	GB	Aspire Pharma Ltd.	26 Apr 1995
Pruritus	GB	Aspire Pharma Ltd.	26 Apr 1995
Eczema	JP	Shionogi & Co., Ltd.	29 Mar 1988
Erythema	JP	Shionogi & Co., Ltd.	29 Mar 1988
Insect Bites and Stings	JP	Shionogi & Co., Ltd.	29 Mar 1988
Keratoderma, Palmoplantar	JP	Shionogi & Co., Ltd.	29 Mar 1988
Lichen Planus	JP	Shionogi & Co., Ltd.	29 Mar 1988
Lupus Erythematosus, Discoid	JP	Shionogi & Co., Ltd.	29 Mar 1988
Prurigo	JP	Shionogi & Co., Ltd.	29 Mar 1988
Psoriasis	JP	Shionogi & Co., Ltd.	29 Mar 1988
Purpura	JP	Shionogi & Co., Ltd.	29 Mar 1988
Roseolovirus Infections	JP	Shionogi & Co., Ltd.	29 Mar 1988

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01465802 (ARCHER 1042, CTgov)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	236	Placebo+Doxycycline+Dacomitinib (Cohort I: Arm A (Dacomitinib 45 mg + Doxycycline Placebo))	opuzldtrkw(xviypltjxg) = hnhkothcuf ghthremcmy (tbnusujctd, nsuzdtnieh - qoevmioens) View more	-	17 Aug 2016
				Doxycycline+Dacomitinib (Cohort I: Arm B (Dacomitinib 45 mg + Doxycycline 100 mg))	opuzldtrkw(xviypltjxg) = ynhcoivvnk ghthremcmy (tbnusujctd, xslormitzo - kdgjxoxszp) View more
NCT01465802 (ARCHER 1042, WCLC2015)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	112	Dacomitinib 45 mg + placebo	aomdzldaxx(wzcbocuaez) = improved with prophylactic doxy, but not alclo; prophylactic probiotic was not associated with improved CTCAE or PRO otmlykvrnd (efiivbkhvo )	-	08 Sep 2015
				Dacomitinib 45 mg + Doxycycline 100 mg